Navigation Links
Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media

ATLANTA, Oct. 24, 2013 /PRNewswire-iReach/ -- Jeevan BioSciences, Inc. ( a start-up biotechnology company co-founded by Dr. Rodney Nash, PhD, a former Neuroscience Post-Doctoral Fellow at Emory University, today announces the commercial release of its first product Neuro–X Tissue Culture Media; the first 100% Serum Free and Xeno Free media product available on the market. Neuro-X is a proprietary patent pending chemically defined media specifically formulated for use in the growth of human cells and tissue without the need for serum or other animal products. The product was originally developed to support the growth of neuronal cells, but has been engineered to support the growth of multiple types of human cells including U87, HeLa, Neural progenitors, MCF7, Raji, A549, 143B, HS587T, PSCs, Cancer Stem Cells, Foreskin Fibroblasts, as well as MEF and 3T3 mouse cells. Researchers using Neuro-X are discovering that the product supports additional cell types on an almost weekly basis.

"It is well known that serum is essentially a contaminant that significantly affects the ability to obtain reliable and reproducible results when it comes to cell culturing, and we knew that developing a serum free and xeno free media would solve this problem," says Dr. Rodney Nash, CEO of Jeevan BioScience.

Neuro-X is a proprietary DMEM/F-12 base media that contains no animal-derived components or albumin, and efficiently grows all types of human cells and tissue including cancer cells, stem cells, neuronal cells, foreskin fibroblast, and muscle cells. The media also effectively grows mouse cells and other tissue as well. "We are excited about the possibilities when you consider the number of different cell types that Neuro-X supports," continues Dr. Nash; "we constantly hear about additional cell types that the media supports from other researchers around the country that are using the media, and we encourage them to run new experiments and expand the possibilities of their research".

"This media maintains stemness in neuronal progenitor cells" says Dr. Jie Xu, Ph.D. a researcher at Georgia State University.; "we have been able to successfully infect these cells with Sindbis virus and maintain neuronal progenitor cells using Neuro-X media, and now we intend to include this media as an important tool in our research initiatives." Neuro-X media is also being used by cancer researchers across the country. "We are very impressed with Neuro-X in maintaining and differentiating patient glioma tumor-derived (primary cells) cancer stem cell," says Carol Tucker-Burden a researcher at Emory University, "the Neuro-X media maintains the tumor derived neurospheres similarly in comparison to our supplemented media without the need for us to be concerned with serum, which we consider to be a contaminant."

Neuro-X is available at an introductory price of US$199.00 per 500ML bottle, and is distributed by World Wide Medical Products, Inc. (, a laboratory products and services company located in Bristol Pennsylvania. "We are very impressed with the Neuro-X product and the team at Jeevan Biosciences," says David Spaventa, Director of Sales & Strategic Alliances at World Wide Medical Products; "prior to our relationship with Jeevan we had never distributed a media product, but decided to distribute Neuro-X given its unique quality as the only true serum free and xeno free media available on the market, and the significant growth potential for a product like this". Free samples of Neuro-X media are available in units of 50mL and 100mL from World Wide Medical Products (1-866-889-9967)

Additional information about the Neuro-X product can be found on the Jeevan Biosciences website (,) including product brochures and scientific papers that provide technical details about how the media is being used in scientific research and drug development.

About Jeevan Bio Sciences, Inc. 
Jeevan Biosciences, Inc. is an Atlanta based biotechnology company committed to the development of cellular models for cancer and neurologic disease research and drug testing. Through accurate cellular model systems, we strive to bridge the gap between research and medicine to improve the quality of life for patient populations who would benefit the most.

Media Contact: Dr. Rodney Nash, Jeevan Biosciences,Inc., (404) 921-2505,

News distributed by PR Newswire iReach:

SOURCE Jeevan BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
4. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
6. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
7. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
8. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
9. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
10. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
11. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The recently published 32nd Annual Report of ... that in 2014, someone called a poison center about every 11 seconds. America’s ... human exposure cases. , The American Association of Poison Control Centers (AAPCC) maintains ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast ... and prevention—is joining forces with the award-winning creator and writer of Downton Abbey ... 7, 2015 at the Union League of Philadelphia. , The benefit, titled ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about ... baby had high blood pressure due to loud noises," she said, "so I decided ... noise pollution as well as radio waves and microwaves." , The baby BABY MUFF ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
Breaking Medicine News(10 mins):